Infections due to Candida spp in a Brazilian Tertiary Hospital: Species and Susceptibility to Antifungals
DOI:
https://doi.org/10.21270/archi.v11i4.5800Palavras-chave:
Candida, Hospital Infections, Microbial Sensitivity, Tests, Antifungals AgentsResumo
Introduction: Infections caused by Candida spp are a major public health concern, due to the high mortality rate and the limited therapeutic arsenal. Objectives: To assess the prevalence of Candida spp infections and susceptibility to antifungal agents in a general hospital. Methods: Descriptive, cross-sectional study with collection of epidemiological and laboratory data on Candida spp cultures (2014 to 2019), at a large tertiary and philanthropic hospital in the city of Piracicaba, São Paulo state, Brazil. Results: A total of 63 episodes of Candida spp infection were eligible, being more prevalent in adults (88.9%) aged ≥ 70 years (41.3%), causing 40 deaths (63.5%). The C. albicans species represented 41.3% of the infections, with a mortality rate of 37.5%, while non-albicans species accounted for 58.7%, highlighting C. tropicalis (25.4%) and C. glabrata (23.8%), with a mortality rate of 27.5% for both species. Regarding the susceptibility profile, most were sensitive to echinocandins and azoles over the years. C. glabrata presented one case of resistance and dose-dependent sensitivity to caspofungin and micafungin and fluconazole, which was expected due to the decreased sensitivity to azoles, while the results for echinocandins were in agreement with previous studies showing increased resistance to this group of drugs. Conclusion: Given the high prevalence of hospital fungal infections and the associated mortality rate, determining the local epidemiological profile and susceptibility to drugs is an important strategy for guiding antifungal therapy.
Downloads
Referências
Kucukates E, Gultekin NN, Alisan Z, Hondur N, Ozturk R. Identification of Candida species and susceptibility testing with sensititre yeastone microdilution panel to 9 antifungal agents. Saudi Med J. 2016;37(7):750-57.
Kaur H, Shankarnarayana SA, Hallur V, Muralidharan J, Biswal M, Ghosh AK, et al. Prolonged Outbreak of Candida krusei Candidemia in Paediatric Ward of Tertiary Care Hospital. Mycopathologia. 2020;185(2):257-68.
Jahagirdar VL, Davane MS, Aradhye SC, Nagoba BS. Candida species as potential nosocomial pathogens - A review. Electron J Gen Med. 2018;15(2):4.
Delavy M, Dos Santos AR, Heiman CM, Coste AT. Investigating Antifungal Susceptibility in Candida Species With MALDI-TOF MS-Based Assays. Front Cell Infect Microbiol. 2019;9:19.
Wiederhold NP. The antifungal arsenal: alternative drugs and future targets. Int J Antimicrob Agents. 2018;51(3):333-39.
Ohshima T, Ikawa S, Kitano K, Maeda N. A proposal of remedies for oral diseases caused by Candida: A mini review. Front Microbiol. 2018;9:1-7.
Bertolini M, Ranjan A, Thompson A, Diaz PI, Sobue T, Maas K, et al. Candida albicans induces mucosal bacterial dysbiosis that promotes invasive infection. PLoS Pathog. 2019;15(4): e1007717.
Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Prim. 2018;4:1-20.
Corsi-Vasquez G, Ostrosky-Zeichner L. Candida auris: What have we learned so far? Curr Opin Infect Dis. 2019;559-64.
Turan H, Demirbilek M. Biofilm-forming capacity of blood–borne Candida albicans strains and effects of antifungal agents. Rev Argent Microbiol. 2018;50(1):62-9.
Colombo AL, Guimarães T. Epidemiology of hematogenous infections due to Candida spp. Rev Soc Bras Med Trop. 2003;36(5):599-607.
Baman JR, Medhekar AN, Jain SK, Knight BP, Harrison LH, Smith B et al. Management of systemic fungal infections in the presence of a cardiac implantable electronic device: A systematic review. Pacing Clin Electrophysiol. 2021;44(1):159-66.
Marol S, Yücesoy M. Molecular epidemiology of Candida species isolated from clinical specimens of intensive care unit patients. Mycoses. 2008;51(1):40-9.
Doğan Ö, Yeşilkaya A, Menekşe Ş, Güler Ö, Karakoç Ç, Çınar G et al. Effect of initial antifungal therapy on mortality among patients with bloodstream infections with different Candida species and resistance to antifungal agents: A multicentre observational study by the Turkish Fungal Infections Study Group. Int J Antimicrob Agents. 2020;56(1):105992.
Taei M, Chadeganipour M, Mohammadi R. An alarming rise of non-albicans Candida species and uncommon yeasts in the clinical samples; a combination of various molecular techniques for identification of etiologic agents. BMC Res Notes. 2019;12(1):1-7.
Colombo AL, Nucci M, Park BJ, Nouér SA, Arthington-Skaggs B, Da Matta DA et al. Epidemiology of candidemia in Brazil: A nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol. 2006;44(8):2816-23.
Robbins N, Wright GD, Cowen LE. Antifungal drugs: The current armamentarium and development of new agents. The Fungal Kingdom. 2017;(1):903-22.
Althaus VA, Regginato A, Bossetti V, Schmidt JC. Candida spp. in clinical isolates and susceptibility to antifungal agents in hospitals. Rev Saúde e Pesqui. 2015;(8):7-17.
Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, et al. Epidemiology of candidaemia in Europe: Results of 28-Month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis. 2004;23(4):317-22.
Arendrup MC. Candida and candidaemia. Susceptibility and epidemiology. Dan Med J. 2013;60(11):B4698.
Tiraboschi IN, Pozzi NC, Farías L, García S, Fernández NB. Epidemiología, especies, resistencia antifúngica y evolución de las candidemias en un hospital universitario de Buenos Aires, Argentina, durante 16 años Rev Chilena Infectol. 2017;34(5):431-40.
Pristov KE, Ghannoum MA. Resistance of Candida to azoles and echinocandins worldwide. Clin Microbiol Infect.2019;25(7):792-8.
Chermont AG, Rodrigues RAA, Praxedes FB, Monma CA, Pinheiro RET, Nascimento LCC. Candidemia em unidade materno infantil de referência: aspectos clínico-epidemiológicos e fatores de risco em prematuros com peso inferior a 1.500 g. Rev Pan-Amaz Saude. 2015; 6(4):35-8.
Braga PR, Cruz IL, Ortiz I, Barreiros G, Nouér SA, Nucci M. Secular trends of candidemia at a Brazilian tertiary care teaching hospital. Brazilian J Infect Dis. 2018;22(4):273–7.
Van Asbeck E, Clemons K V., Martinez M, Tong AJ, Stevens DA. Significant differences in drug susceptibility among species in the Candida parapsilosis group. Diagn Microbiol Infect Dis. 2008;62(1):106-9.
Fernandes ACS, De Sousa FC, De Oliveira SM, Calich L, Milan EP. Prevalence of Candida species in umbilical catheters implanted in newborns in Natal, Brazil. Brazilian J Microbiol. 2007;38(1):104-7.
Xavier PCN, Chang MR, Nunes MO, Palhares DB, Silva RA, Bonfim GF, et al. Neonatal candidemia in a public hospital in Mato Grosso do Sul. Rev Soc Bras Med Trop. 2008;41(5):459-63.
Hinrichsen SL, Falcão É, Vilella TAS, Colombo AL, Nucci M, Moura L, et al. Candidemia em hospital terciário do nordeste do Brasil. Rev Soc Bras Med Trop. 2008;41(4):394-8.
Alves PGV, Melo SGO, Bessa MA de S, Brito M de O, Menezes R de P, de Araújo LB, et al. Risk factors associated with mortality among patients who had candidemia in a university hospital. Rev Soc Bras Med Trop. 2020;53:1-5.
Maubon D, Garnaud C, Calandra T, Sanglard D, Cornet M. Resistance of Candida spp. to antifungal drugs in the ICU: Where are we now? Intensive Care Med. 2014;40(9):1241–55.
Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R, et al. Increasing echinocandin resistance in candida glabrata: Clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013;56(12):1724-32.
